aTYR PHARMA INC — Director's Dealing 2023

Apr 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2023-04-26

Reporting Person: Zaknoen Sara (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-26	Common stock	M	6000	—	Acquired	6000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-26	Restricted Stock Unit	$	M	6000	Disposed		Common Stock (6000)	Direct

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022.

F2: RSUs convert into common stock on a one-for-one basis.

F3: The RSUs fully vested one year from the grant date which was April 26, 2022.